Medico Remedies Ltd

Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 July 2026. This shift reflects a combination of deteriorating technical indicators, subdued long-term growth prospects, and mixed financial performance despite recent quarterly improvements. The company’s Mojo Score now stands at 47.0, signalling caution for investors amid a challenging market backdrop.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 2 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 23 June 2026. This change reflects a deterioration in technical indicators alongside concerns over the company’s long-term growth prospects despite recent positive quarterly financial results.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 16 June 2026. This change reflects a nuanced improvement across technical indicators, financial performance, valuation metrics, and overall quality assessments, signalling a cautious but positive outlook for investors.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a combination of deteriorating technical indicators, tempered long-term growth prospects, and valuation concerns despite recent positive quarterly financial results.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Medico Remedies Ltd., a micro-cap pharmaceutical manufacturer, delivered a robust performance in Q4 FY26 (January-March 2026) with net profit surging 35.02% year-on-year to ₹5.86 crores, marking the company's strongest quarterly earnings to date. However, the quarter-on-quarter decline of 3.19% in revenue and persistent margin volatility have raised questions about the sustainability of this growth trajectory for the ₹389.69 crore market capitalisation company.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Medico Remedies Ltd has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026, driven primarily by deteriorating technical indicators despite some positive financial trends. The micro-cap pharmaceutical company’s current Mojo Score stands at 47.0, reflecting a cautious outlook amid mixed signals across quality, valuation, financial trend, and technical parameters.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 22 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall company quality, signalling a cautious but positive outlook for investors amid mixed long-term performance.

Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell despite an upgrade in its valuation grade from fair to attractive. This shift, effective from 1 April 2026, reflects a complex interplay of factors including valuation metrics, financial trends, quality assessments, and technical indicators, which together paint a nuanced picture for investors.

For the fifth consecutive session, Medico Remedies Ltd has closed lower, culminating in a fresh 52-week low of Rs 31 on 30 Mar 2026. This decline comes amid a broader market downturn, but the stock's underperformance is notably sharper than its sector peers.

Medico Remedies Ltd has seen its investment rating upgraded from Sell to Hold as of 27 March 2026, reflecting a marked improvement in valuation metrics and financial performance despite recent share price weakness. The pharmaceutical company’s enhanced score is driven primarily by a shift to an attractive valuation grade, supported by robust return on capital employed (ROCE), steady financial trends, and a cautiously optimistic technical outlook.

Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, reflecting a more compelling price proposition for investors. Despite recent share price declines, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest improved relative value compared to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.